Average Co-Inventor Count = 3.77
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Ogeda Sa (18 from 23 patents)
2. Tranzyme Pharma Inc. (11 from 19 patents)
3. Ocera Therapeutics, Inc. (4 from 26 patents)
4. Euroscreen S.a. (3 from 33 patents)
5. Epics Therapeutics (1 from 6 patents)
6. Oged Sa (1 from 1 patent)
38 patents:
1. 12458641 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
2. 12091400 - Piperidine derivatives as METTL3 inhibitors
3. 11731974 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
4. 11478472 - NK-3 receptor antagonists for therapeutic treatment of leptin-related disease
5. 10941151 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
6. 10836768 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
7. 10683295 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
8. 10624890 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
9. 10544150 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
10. 10258602 - Macrocyclic ghrelin receptor modulators and methods of using the same
11. 10214533 - N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
12. 10183948 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
13. 10065961 - Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
14. 10065960 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
15. 10030025 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists